It will all depend on the clinical, and they only have 3 months...

It will all depend on the clinical, and they only have 3 months left to get it done. If that is successful, they will likely be first (or at least very early) to market for over the counter. If it fails, it could be completely dead although the price may already reflect anticipation of that given CAN's failure.

I remain confident it will succeed because the language used in all the reports is very confident (bordering on dangerous) and I hope they wouldn't use that language unless they were near certain it was going to work.